Asset Dedication LLC Grows Holdings in Danaher Co. (NYSE:DHR)

Asset Dedication LLC raised its position in Danaher Co. (NYSE:DHR) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,099 shares of the conglomerate’s stock after buying an additional 122 shares during the period. Asset Dedication LLC’s holdings in Danaher were worth $1,418,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Oak Thistle LLC purchased a new stake in shares of Danaher during the second quarter valued at approximately $363,000. Norden Group LLC bought a new stake in shares of Danaher during the 1st quarter worth $4,151,000. Duality Advisers LP purchased a new position in shares of Danaher in the 1st quarter worth about $5,573,000. Investment Research & Advisory Group Inc. bought a new position in Danaher during the first quarter valued at about $1,186,000. Finally, Diversified Trust Co increased its holdings in Danaher by 75.4% during the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after buying an additional 1,874 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Finally, Stephens started coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Stock Down 1.7 %

Shares of NYSE:DHR opened at $267.99 on Thursday. The company has a market cap of $198.50 billion, a price-to-earnings ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The firm has a fifty day moving average price of $270.53 and a two-hundred day moving average price of $259.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business earned $2.05 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. Analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last three months. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.